Calypso Biotech Company

Calypso Biotech is a biopharmaceutical company founded in 2013 as a spin-off from Merck Serono. They are based in Geneva, Switzerland and were initially financed through a 2.5 million euro seed-fund managed by MS Ventures. Calypso Biotech is managed by a highly experienced team with strong expertise in drug development and an extensive scientific and industry network. They operate as a nimble, semi-virtual organization to create added value for their investors from a portfolio of unique proprietary antibody candidates.

Invests into

Investors

Connections

Headquarters: Geneva
Industry: PharmTech
Register and Claim Ownership